NK 012

Drug Profile

NK 012

Alternative Names: NK012; Polymeric micelle camptothecin analogue - Nippon Kayaku

Latest Information Update: 06 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nippon Kayaku
  • Class Antineoplastics; Camptothecins
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer; Multiple myeloma; Small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 31 Jul 2015 NK 012 is still in phase II trials for Multiple myeloma in Japan
  • 08 Jun 2015 Phase-II development is ongoing for breast cancer, colorectal cancer, small cell lung cancer in USA and Japan
  • 01 Feb 2015 Nippon Kayaku completes a phase II trial in Breast cancer (Second-line therapy or greater, metastatic disease) in USA (NCT00951054)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top